High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

During September’s Prostate Cancer Awareness Month, MidLantic Urology is reminding men of a critical point. It's 0.75. If your PSA increases by 0.75 in 1 year, it could be prostate cancer, and it’s ...

ATLANTA - Each year, millions of American men get a blood test known as a PSA, or prostate-specific antigen, test as part of their yearly checkup. PSA is a protein produced by the prostate gland. If a ...

I am a 68-year old male in good health who exercises regularly, doesn’t take any medications, and doesn’t have a family history of prostate cancer. During my most recent yearly physical exam with my ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific ...

News that former President Joseph Biden has advanced prostate cancer has revived long-standing questions about the benefits versus the harms of a blood test that screens for the most commonly ...

ROSEVILLE, California — President Joe Biden's recent prostate cancer diagnosis is raising new questions about the disease and the value of screenings for men. Dr. David Yee, director of Urology and ...

To date, men undergoing screening through the measurement of prostate-specific antigen (PSA) levels have had a significant reduction in neoplastic mortality. Because of its low specificity, however, ...

A diagnosis of prostate cancer is a kick in the proverbial slats. Really. You don’t want to hear the word, “cancer,” at all…anytime…ever. But if you’re ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...